Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 5:09 AM
Ignite Modification Date:
2025-12-26 @ 4:13 AM
NCT ID:
NCT02515227
Group ID:
EG000
Title:
6MHP + Pembrolizumab (PD-1 Antibody-naive Cohort)
Description:
Participants who had not previously received a PD-1 or PD-L1 antibody were eligible for this cohort.
They received 6MHP vaccine (200 mcg each peptide) emulsified in Montanide ISA-51 adjuvant and administered intradermally and subcutaneously on days 1, 8, 15, 43, 64, and 85. Pembrolizumab (200 mg) was administered intravenously every 3 weeks for up to 2 years, beginning on day 1.
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
Pembrolizumab: Humanized monoclonal antibody (mAb) specific for PD-1.
Deaths Number Affected:
0
Deaths Number At Risk:
None
Serious Number Affected:
0
Serious Number At Risk:
6
Other Number Affected:
6
Other Number At Risk:
6
Study:
NCT02515227
Results Section:
NCT02515227
Adverse Events Module:
NCT02515227